maximizing the potential of parp inhibitors as first-line maintenance therapy in ovarian cancer
Published 2 years ago • 90 plays • Length 35:35Download video MP4
Download video MP3
Similar videos
-
59:02
parp inhibitors as first-line maintenance therapy in ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
39:03
the therapeutic potential of novel parp inhibitors in the clinic for epithelial ovarian cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors
-
9:47
can parp inhibitors offer benefit for all patients with platinum-sensitive ovarian cancer?
-
4:12
parp inhibitors
-
17:35
expert perspectives: the clinical potential of parp inhibitors in ovarian cancer
-
2:22
dr. konecny on the value of parp inhibitors in ovarian cancer
-
1:26
parp inhibitors for maintenance therapy in ovarian cancer
-
34:13
expert views on the evolving role of parp inhibitors in the treatment of ovarian cancer
-
1:08
should 1l maintenance with parp inhibitors be given to all patients with ovarian cancer?
-
1:10:07
optimizing the use of parp inhibitors in ovarian cancer
-
1:53
parp inhibitors: game-changers for ovarian cancer patients?
-
19:09
ecco 2017 - a new parp inhibitor to clinical practice - part 4
-
0:59
the evolution of parp inhibitors in ovarian cancer
-
24:56
gynecologic cancer education: parp inhibitor therapy
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches